Trial Profile

Phase 2 clinical trial of APX3330 in patients with Diabetic-macular-oedema

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 26 Dec 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs APX 3330 (Primary)
Indications Diabetic macular oedema
Focus Proof of concept; Therapeutic Use

Most Recent Events

03 Nov 2020 According to an Ocuphire Pharma media release, data from this trial will be presented at Key Opinion Leader (KOL) webinar
17 Jun 2020 According to a Rexahn Pharmaceuticals media release, the company expect to initiate this trial in the second half of 2020 and topline results are expected as early as the first quarter of 2021 and throughout the remainder of 2021.
29 Jan 2020 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com